Premature Ejaculation – Pipeline Review, H1 2013

Description: Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Premature Ejaculation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Premature Ejaculation.
- A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Premature Ejaculation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Premature Ejaculation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Premature Ejaculation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Premature Ejaculation Overview
Therapeutics Development
An Overview of Pipeline Products for Premature Ejaculation
Premature Ejaculation Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Premature Ejaculation Therapeutics – Products under Development by Companies
Companies Involved in Premature Ejaculation Therapeutics Development
GlaxoSmithKline plc
Vectura Group plc
Dong-A Pharmaceutical Co., Ltd.
Futura Medical plc.
Plethora Solutions Holdings plc
Medisyn Technologies, Inc.
NeuroHealing Pharmaceuticals Inc.
Ampio Pharmaceuticals, Inc.
Premature Ejaculation – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(lidocaine + prilocaine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VR-776 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
modafinil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-8031 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epelsiban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dapoxetine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
clomipramine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Premature Ejaculation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tramadol hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TUC-204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Sexual Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NCE-405 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Premature Ejaculation Therapeutics – Drug Profile Updates
Premature Ejaculation Therapeutics – Discontinued Products
Premature Ejaculation Therapeutics - Dormant Products
Premature Ejaculation – Product Development Milestones
Featured News & Press Releases
Sep 12, 2012: Ampio Pharma Signs Manufacturing Agreement With Ethypharm For Zertane
Jul 02, 2012: Ampio Pharma Contracts With Syngene To Manufacture Zertane-ED To Treat Both Premature Ejaculation And Erectile Dysfunction
Jun 21, 2012: Ampio Pharma Reports Successful Type B Pre-IND Meeting With FDA For Zertane To Treat Premature Ejaculation
Jun 11, 2012: Plethora Provides PSD502 Regulatory Submission Update
Apr 09, 2012: Ampio Submits Type B Pre IND Meeting Request To FDA For Zertane
Apr 02, 2012: Ampio Reaches Agreement With Therapeutic Goods Administration For Submission Plan For Zertane In Australia
Mar 15, 2012: Plethora Provides Update On Regulatory Submission Of PSD502
Jan 31, 2012: European Commission Endorses Positive Opinion Of Priligy For On-demand Treatment Of Premature Ejaculation In All EU Countries
Jan 17, 2012: Ampio's Zertane Combinations To Receive Two New European Patents For Treatment Of Male Sexual Dysfunctions
Jan 17, 2012: Apricus Bio Announces Allowance Of Israeli Patent For Vitaros For Topical Treatment Of Premature Ejaculation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Premature Ejaculation, H1 2013
Products under Development for Premature Ejaculation – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
GlaxoSmithKline plc, H1 2013
Vectura Group plc, H1 2013
Dong-A Pharmaceutical Co., Ltd., H1 2013
Futura Medical plc., H1 2013
Plethora Solutions Holdings plc, H1 2013
Medisyn Technologies, Inc., H1 2013
NeuroHealing Pharmaceuticals Inc., H1 2013
Ampio Pharmaceuticals, Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Premature Ejaculation Therapeutics - Drug Profile Updates
Premature Ejaculation Therapeutics - Discontinued Products
Premature Ejaculation Therapeutics – Dormant Products

List of Figures

Number of Products under Development for Premature Ejaculation, H1 2013
Products under Development for Premature Ejaculation – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Combination Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2497104/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Premature Ejaculation – Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2497104/
Office Code: SCD21WW3

Product Formats
Please select the product formats and quantity you require:

Quantity
Electronic (PDF) - Single User: □ USD 2000
Electronic (PDF) - Site License: □ USD 4000
Electronic (PDF) - Enterprisewide: □ USD 6000

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr  □  Mrs  □  Dr  □  Miss  □  Ms  □  Prof  □
First Name: ........................................  Last Name: ........................................
Email Address: * ........................................
Job Title: ........................................
Organisation: ........................................
Address: ........................................
City: ........................................
Postal / Zip Code: ........................................
Country: ........................................
Phone Number: ........................................
Fax Number: ........................................

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
  27-35 Main Street,
  Blackrock,
  Co. Dublin,
  Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World